Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Jill Henrich Sells 1,000 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Jill Henrich sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $11.20, for a total value of $11,200.00. Following the completion of the sale, the executive vice president now directly owns 19,378 shares of the company’s stock, valued at $217,033.60. The trade was a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Atara Biotherapeutics Trading Down 2.8 %

ATRA traded down $0.31 on Wednesday, hitting $10.68. 108,460 shares of the company’s stock were exchanged, compared to its average volume of 107,467. The firm has a 50-day moving average price of $9.09 and a 200-day moving average price of $10.10. The stock has a market cap of $61.52 million, a price-to-earnings ratio of -0.41 and a beta of 0.50. Atara Biotherapeutics, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter last year, the company earned ($16.50) earnings per share. On average, equities analysts predict that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current year.

Institutional Trading of Atara Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Atara Biotherapeutics by 8,916.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock worth $3,442,000 after acquiring an additional 4,903,159 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Atara Biotherapeutics by 49.5% during the first quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after buying an additional 873,133 shares during the period. Redmile Group LLC boosted its holdings in Atara Biotherapeutics by 1.7% during the 1st quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after acquiring an additional 156,863 shares during the period. BNP Paribas Financial Markets increased its stake in Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after buying an additional 86,842 shares during the period. Finally, Delap Wealth Advisory LLC acquired a new stake in shares of Atara Biotherapeutics in the first quarter valued at $29,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their target price for the stock from $25.00 to $18.00 in a research note on Friday, August 16th. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. Finally, Canaccord Genuity Group lifted their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Atara Biotherapeutics has an average rating of “Hold” and an average target price of $16.67.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.